Articles for category: Most Popular

Can STERIS Stock Deliver as Its $600 Million Chemistry Bet Scales?

STERIS plc STE is making its largest-ever investment in a single manufacturing site with a $600 million formulated chemistries Center of Excellence in North Carolina. The project is designed to expand capacity, improve efficiency and support long-term demand across key parts of its portfolio. The opportunity is meaningful, but so is the execution burden. Investors ...

Forget Robotaxi and Optimus: Billionaire Stanley Druckenmiller May Have Invested in Tesla for a Very Different Reason

Key Points Many Tesla bulls have high conviction about the company’s AI infrastructure efforts, Optimus and Robotaxi. For now, Optimus has yet to be deployed commercially, while Robotaxi’s growth has been uninspiring. Druckenmiller’s options may still prove profitable, as many investors are likely overlooking a key performance metric. These 10 stocks could mint the next ...

Alibaba Cloud Revenue Jumps 45%. Is the Profit Plunge and China E-Commerce Slide Cause for Concern?

Key Points It fell well short of analyst profitability estimates, although its revenue was essentially in line. Investors clearly chose to focus on the positive developments in the quarter, particularly the company’s leap in revenue from next-generation tech offerings. 10 stocks we like better than Alibaba Group › Alibaba Group (NYSE:BABA), which shot to fame ...

SPOT Gains 12.5% in a Month as Growth Strength Meets Valuation Risk

Spotify Technology S.A. SPOT shares have gained 12.5% over the past four weeks, renewing attention on whether improving operating performance can support further upside. A record gross margin, subscriber growth and better monetization strengthen the fundamental case. Still, a premium valuation, softer estimate revisions and planned reinvestment leave little room for execution slippage. SPOT’s Profit ...

Is NBIX Stock a Buy as Fast Growth Meets a Premium Sales Valuation?

Neurocrine Biosciences, Inc. NBIX is pairing rapid earnings and revenue growth with a broader rare-disease portfolio. That operating momentum gives investors a clear fundamental reason to watch the stock. The trade-off is valuation and execution. NBIX sells at a premium to its sub-industry and the Medical sector on forward sales, while product concentration, competition and ...

Will Higher Bond Yields Break the AI Bull Market?

Listen to the audio version of this article (generated by AI). Checking in on the bond market… Washington’s $4 billion bandaid… why the vigilantes are furious at Warsh… Luke Lango’s 5% line in the sand… the number Yardeni is watching As I write on Wednesday, the bond market just got rescued…for the moment. Yesterday, the ...